Lynch Syndrome (LS) is a common hereditary condition that greatly increases lifetime risk of colorectal, endometrial, urothelial and other ...

A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...

MDX2004 is designed to activate T cells through three unique signalling pathways to enhance immune activation.

Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover ...

The understanding of immune biology and the development of newer generations of immunotherapies have opened a new stage to ...

ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company ...

Enterome, a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, has announced that the US ...

AI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific ...

Professor Guan Xinyuan (left) and his research team developed the 'Cancer Immunology Data Engine', which is publicly ...

First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, ...

Real-time index price for TSX Venture Composite Index (JX), along with buy or sell indicators, analysis, charts, historical ...

Detailed price information for Knight Therapeutics Inc (GUD-T) from The Globe and Mail including charting and trades.